Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | USP2 | O75604 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375730 | 0.82 | APP (0.38) | CYP1A2CYP2C19ALDH1A1CA12CA1 | |
| SCHEMBL12151159 | 0.77 | KDM4E (0.38) | CYP1A2CYP2C19KDM4EGLAGAA | |
| SCHEMBL31741854 | 0.72 | CYP1A2 (0.54) | CYP1A2CYP2C19ALDH1A1USP2CA12 | |
| SCHEMBL13575701 | 0.70 | NR1H2 (0.53) | CYP1A2CYP2C19ALDH1A1USP2CA12 | |
| SCHEMBL788649 | 0.70 | KDM4E (0.34) | CYP1A2CA12CA1CA2CA7 | |
| SCHEMBL23940967 | 0.69 | ALDH1A1 (0.50) | ALDH1A1LMNAADORA3HPGDKDM4E | |
| SCHEMBL6493171 | 0.69 | KDM4E (0.34) | ALDH1A1LMNAMAPK1HPGDKDM4E | |
| SCHEMBL12126788 | 0.69 | CA12 (0.46) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL9038716 | 0.68 | ALDH1A1 (0.42) | ALDH1A1CA1CA2LMNAMAPK1 | |
| SCHEMBL5589707 | 0.67 | LDHA (0.45) | CYP1A2CYP2C19ALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139604-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2015-01-22 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | CANNIZZARO CARINA | 2009-10-01 | — | — | US | disclosed |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | CANNIZZARO CARINA | 2009-09-10 | — | — | US | disclosed |
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | GILEAD SCIENCES, INC. | 2006-02-16 | — | — | US | disclosed |
| EP-1620110-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2005-11-17 | — | — | US | disclosed |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | GILEAD SCIENCES, INC. | 2005-09-29 | — | — | US | disclosed |
| WO-2004100960-A2 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096236-A2 | IMMUNOMODULATOR PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035866-A1 | Phosphonate compounds having immuno-modulatory activity | PHOSPHO1, NFATC1, IFNG | CYP1A2 4725/4885CYP2C19 4570/4885ALDH1A1 4028/4885 |
| US-20150025039-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CYP1A2 4769/4885CYP2C19 4055/4885ALDH1A1 4754/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CYP1A2 4769/4885CYP2C19 4055/4885ALDH1A1 4754/4885 |
| US-20130316969-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CYP1A2 4769/4885CYP2C19 4055/4885ALDH1A1 4754/4885 |
| US-20090227543-A1 | PHOSPHONATE COMPOUNDS HAVING IMMUNO-MODULATORY ACTIVITY | PHOSPHO1, NFATC1, IFNG | CYP1A2 4725/4885CYP2C19 4570/4885ALDH1A1 4028/4885 |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CYP1A2 4769/4885CYP2C19 4055/4885ALDH1A1 4754/4885 |
| US-20050215513-A1 | Use of an antiviral compound linked to one or more phosphonate groups in hepatitis C treatment; improved bioavailability, side effect reduction; antiviral compound is a 2-(2-isopropylaminothiazol-4-yl)-4-(tricyclic fused ring)-7-methoxy-quinoline compound | EIF2AK2, PNP, NUDT1 | CYP1A2 1389/4885CYP2C19 1241/4885ALDH1A1 3720/4885 |
| US-20090247488-A1 | ANTI-INFLAMMATORY PHOSPHONATE COMPOUNDS | PHOSPHO1, TNF, PTGES | CYP1A2 3531/4885CYP2C19 2344/4885ALDH1A1 3467/4885 |
| US-20050256078-A1 | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds | IMPDH1, IMPDH2, ITPA | CYP1A2 1706/4885CYP2C19 2070/4885ALDH1A1 312/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | CYP1A2 4831/4885CYP2C19 4604/4885ALDH1A1 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.